[Pharmacological and clinical profile of afatinib (Giotrif®)].
Nozomu
N
Takahashi
Shinobu
S
Suzuki
Kenji
K
Sakai
Hisaya
H
Azuma
D000077716:Afatinib; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009154:Mutation; D011799:Quinazolines / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077716:Afatinib; C512478:EGFR protein, human; D066246:ErbB Receptors